Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content
NCT ID: NCT00476879
Last Updated: 2008-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2006-08-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Growth Hormone Replacement on Liver Fat
NCT00774579
Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting
NCT02500095
Growth Hormone Signaling in Vivo in Humans
NCT00512473
Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle
NCT03878992
Effect of Growth Hormone on Insulin Signaling in Muscle Tissue
NCT00477997
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
10 healthy lean young men are studied at 4 different occasions in a randomized single-blinded cross-over study. 1: after 12 hours of fasting + GH bolus, 2: after 36 hours of fasting + GH bolus, 3: after 36 hours + saline, 4: after 36 hours of fasting + Somavert.
Aim:
* to study the signal transduction in muscle and fat tissue
* to study the metabolism during fasting
* to study the intrahepatic fat content using magnetic resonance techniques
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
12 hours of fasting and a GH bolus
Somatropin and pegvisomant
Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
2
36 hours of fasting and a GH bolus
Somatropin and pegvisomant
Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
3
36 hours of fasting and Pegvisomant
Somatropin and pegvisomant
Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
4
36 hours of fasting and NaCl injection
Somatropin and pegvisomant
Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Somatropin and pegvisomant
Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* healthy
* age 20 - 40 years of age
* BMI 20 -25
Exclusion Criteria
* drinks more than 21 units of alcohol per
* is claustrophobic
* carries any magnetic devices
20 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aarhus University Hospital
OTHER
Pfizer
INDUSTRY
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medical department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Louise Moller, MD
Role: PRINCIPAL_INVESTIGATOR
Medical department M, Aarhus Sygehus, Norrebrogade 44, 8000 Aarhus, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical department M, Arhus Sygehus, Region midtjylland
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Moller L, Norrelund H, Jessen N, Flyvbjerg A, Pedersen SB, Gaylinn BD, Liu J, Thorner MO, Moller N, Lunde Jorgensen JO. Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects. J Clin Endocrinol Metab. 2009 Nov;94(11):4524-32. doi: 10.1210/jc.2009-0381. Epub 2009 Oct 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
090600-deleted
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.